ArriVent Biopharma Collaborates with Lepu BioPharma to Develop and Commercialize MRG007 for the Treatment of Gastrointestinal Cancers
Shots:
- ArriVent & Lepu Biopharma entered into an exclusive license agreement for MRG007, where ArriVent will get rights to develop & market MRG007 (ADC) globally excl. Greater China (mainland China, Hong Kong, Macau & Taiwan)
- As per the terms, Lepu Biopharma will receive upfront, near-term milestones ($47M cash) & development, regulatory & sales milestones of ~1.16B, plus net sales-based tiered royalties outside Greater China
- In addition, preclinical studies of MRG007 has demonstrated antitumor activity in GI cancer models & a favorable therapeutic index. IND submission is expected in H1’25, with an initial clinical focus on CRC, pancreatic, & other GI cancers
Ref: Globenewswire | Image: ArriVent & Lepu Biopharma
Related News:- ArriVent BioPharma Collaborates with Alphamab to Develop Antibody Drug Conjugates for Treating Cancers
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
